Stock Financial Ratios, Dividends, Split History

SGY / Stone Energy Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price35.49
Volume205,500.00
Market Cap ($M)709.75
Enterprise Value ($M)668.17
Book Value ($M)326.07
Book Value / Share16.30
Price / Book2.18
NCAV ($M)-162.14
NCAV / Share-8.11
Price / NCAV-4.38
Share Statistics
Common Shares Outstanding 19,998,701
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)n/a
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Assets825.97
Liabilities499.89
Quick Ration/a
Current Ratio2.12
Identifiers and Descriptors
CUSIP861642106
Central Index Key (CIK)904080
Related CUSIPS
861642403 861642304 086164210 861642906 861642114 861642904 861642956 861642954

Split History

Stock splits are used by Stone Energy Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Reverse Merger Listing Of Talos Energy Is An Attractive Investment Opportunity

2018-07-06 seekingalpha
The company is positioned to deliver healthy production growth in FY18-FY20 and for the same period, EBITDA margin is likely to improve as well. (9-0)

Russell 3000 Anomaly: Doubles 2017 Index Returns - 10 New Selections For 2018

2018-06-29 seekingalpha
The 2017 Stock Anomaly selections returned 39.92% compared to 18.63% for the Russell 2000 benchmark index over the same period. (8-0)

[Press] Talos Energy Announces 2018 Financial And Operating Guidance, Provides Initial 2019 Outlook And Operations Update

2018-05-29 oilvoice
HOUSTON, May 29, 2018 /PRNewswire/ -- Talos Energy Inc. ("Talos" or the "Company") (NYSE: TALO) today provided details of the Company's strategy, its key assets and 2018 financial and operating guidance. It also provided an initial outlook for 2019 and an operations update. A presentation containing additional information can be found on the Company's website at www.talosenergy.com in the Investor Relations section. (27-0)

CNX Resources (CNX) Beats Q1 Earnings and Revenue Estimates

2018-05-04 zacks
CNX Resources Corporation (CNX - Free Report) reported adjusted earnings of 19 cents per share in first-quarter 2018, beating the Zacks Consensus Estimate of 12 cents by 58.3%. The bottom line improved 11.8% year over year. Revenues CNX Resources’ total revenues of $495.7 million in the first quarter surpassed the Zacks Consensus Estimate of $406 million by 22.1%. (8-0)

5 Oil Stocks to Buy as Syria Tensions Flare Up

2018-04-17 zacks
The Energy sector has come a long way from the mid-2014 slump. All of us remember the days when explorers had struggled to survive, primarily relying on debt capital and asset sale. After OPEC members decided to curb production to combat the supply glut, crude prices saw a partial recovery. (49-0)

CUSIP: 861642106